Published in J Acquir Immune Defic Syndr on July 01, 2010
Rectal microbicides: can we make them and will people use them? AIDS Behav (2011) 1.41
PrEP awareness and perceived barriers among single young men who have sex with men. Curr HIV Res (2013) 1.38
Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS (2011) 1.22
Preventive misconception and adolescents' knowledge about HIV vaccine trials. J Med Ethics (2013) 1.04
The impact of rapid HIV home test use with sexual partners on subsequent sexual behavior among men who have sex with men. AIDS Behav (2014) 1.02
Routine HIV testing in adolescents and young adults presenting to an outpatient clinic in Durban, South Africa. PLoS One (2012) 1.00
Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr (2011) 0.97
Self-Consent for HIV Prevention Research Involving Sexual and Gender Minority Youth: Reducing Barriers Through Evidence-Based Ethics. J Empir Res Hum Res Ethics (2016) 0.94
Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth. AIDS Patient Care STDS (2012) 0.87
Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials. J Adolesc Health (2014) 0.85
Ethical Issues in Adolescents' Sexual and Reproductive Health Research in Nigeria. Dev World Bioeth (2014) 0.81
HIV Rates Are Increasing in Gay/Bisexual Teens: IRB Barriers to Research Must Be Resolved to Bend the Curve. Am J Prev Med (2016) 0.76
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2007) 13.20
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 10.35
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol (1999) 6.25
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials (2007) 4.93
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
The influence of age on T cell generation and TCR diversity. J Immunol (2005) 4.36
HIV vaccine research: the way forward. Science (2008) 3.86
HIV prevalence, risks for HIV infection, and human rights among men who have sex with men (MSM) in Malawi, Namibia, and Botswana. PLoS One (2009) 3.68
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One (2008) 3.45
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis (2008) 3.31
Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol (1998) 3.08
Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 2.84
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75
Group B streptococcal infections in elderly adults. Clin Infect Dis (2005) 2.59
The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol (2000) 2.52
SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One (2007) 2.41
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2007) 2.22
Aging, immunity, and the varicella-zoster virus. N Engl J Med (2005) 2.20
Whither or wither microbicides? Science (2008) 2.17
Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect (2009) 2.14
Generation of functional thymocytes in the human adult. Immunity (1999) 2.10
Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One (2008) 2.09
Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep (2008) 2.09
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
Multiparameter evaluation of human thymic function: interpretations and caveats. Clin Immunol (2005) 1.97
Growth at puberty. J Adolesc Health (2002) 1.92
HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr (2005) 1.87
Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics (1991) 1.86
Topical microbicides to prevent HIV: clinical drug development challenges. Annu Rev Pharmacol Toxicol (2009) 1.76
Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest (2005) 1.76
Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis (2009) 1.68
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine (2006) 1.57
Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis (2008) 1.57
Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis (2010) 1.55
Tuberculosis immunology in children: diagnostic and therapeutic challenges and opportunities. Int J Tuberc Lung Dis (2004) 1.52
Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci (2009) 1.48
Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056). J Acquir Immune Defic Syndr (2007) 1.46
Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect (2008) 1.41
Microbicides: a new frontier in HIV prevention. Biologicals (2006) 1.35
Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis (2009) 1.25
Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav (2009) 1.20
Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin Pharmacol Ther (2007) 1.19
Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses (2001) 1.19
Age-associated declines in immune system development and function: causes, consequences, and reversal. Curr Opin Immunol (2009) 1.16
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS (2010) 1.15
Relationship of cervical ectopy to chlamydia infection in young women. J Fam Plann Reprod Health Care (2006) 1.13
Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses (2006) 1.11
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS (1999) 1.04
Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr (1999) 1.03
Rectal microbicides: a new focus for HIV prevention. Sex Transm Infect (2008) 1.01
Zidovudine for the reduction of perinatal human immunodeficiency virus transmission: pediatric AIDS Clinical Trials Group Protocol 076--results and treatment recommendations. Pediatr Infect Dis J (1995) 1.00
Therapeutic strategies for chronic hepatitis B virus infection in 2008. Am J Med (2008) 0.98
Thymic volume, T-cell populations, and parameters of thymopoiesis in adolescent and adult survivors of HIV infection acquired in infancy. AIDS (2006) 0.97
HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol (2004) 0.96
The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies. AIDS (2009) 0.95
Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis (2003) 0.94
Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J (2009) 0.93
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS (2010) 0.92
Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS (2001) 0.91
Adolescents' reasons for using a microbicide-like product over time. Int J STD AIDS (2008) 0.88
Relationship context associated with microbicide-like product use. J Pediatr Adolesc Gynecol (2009) 0.87
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig (2007) 0.85
Immunologic susceptibility of young children to Mycobacterium tuberculosis. Pediatr Res (2008) 0.85
Antiretroviral therapy: new drugs, formulations, ideas, and strategies. Top HIV Med (2009) 0.84
Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy. J Clin Virol (2009) 0.82
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis (2008) 0.81
Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency. J Infect (2008) 0.81
Normal physiological and psychosocial growth in the adolescent. J Adolesc Health Care (1986) 0.80
Tenofovir disoproxil fumarate for the treatment of hepatitis B infection. Drugs Today (Barc) (2009) 0.80
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet (2004) 11.28
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Successes and challenges of HIV prevention in men who have sex with men. Lancet (2012) 4.94
Transactional sex among women in Soweto, South Africa: prevalence, risk factors and association with HIV infection. Soc Sci Med (2004) 4.52
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med (2011) 3.46
Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav (2009) 3.29
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med (2008) 2.74
Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.72
CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis (2006) 2.68
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One (2012) 2.53
Feasibility and acceptability of rapid HIV testing in jail. AIDS Patient Care STDS (2007) 2.52
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health (2009) 2.48
Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin Infect Dis (2008) 2.42
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (2005) 2.28
Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata. J Acquir Immune Defic Syndr (2011) 2.27
Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med (2010) 2.26
Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS (2011) 2.21
Prevalence and patterns of gender-based violence and revictimization among women attending antenatal clinics in Soweto, South Africa. Am J Epidemiol (2004) 2.17
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr (2011) 2.16
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (2012) 2.02
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis (2011) 1.99
Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa. J Adolesc Health (2008) 1.97
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.94
Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol (2007) 1.90
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med (2009) 1.90
Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS (2006) 1.88
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure? Clin Infect Dis (2012) 1.86
Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth. J Acquir Immune Defic Syndr (2012) 1.84
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84
Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis (2011) 1.83
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
HIV risk and associations of HIV infection among men who have sex with men in peri-urban Cape Town, South Africa. BMC Public Health (2011) 1.79
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS (2002) 1.78
Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment. S Afr Med J (2011) 1.74
Knowledge and attitudes towards HIV vaccines among Soweto adolescents. BMC Res Notes (2008) 1.72
Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health (2006) 1.71
Body mass index and risk of tuberculosis and death. AIDS (2010) 1.71
Tuberculosis control has failed in South Africa--time to reappraise strategy. S Afr Med J (2011) 1.70
Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr (2011) 1.69
Who gets tested for HIV in a South African urban township? Implications for test and treat and gender-based prevention interventions. J Acquir Immune Defic Syndr (2011) 1.67
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses (2012) 1.67
Breast-feeding, antiretroviral prophylaxis, and HIV. N Engl J Med (2008) 1.66
Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet (2012) 1.65
Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol (2002) 1.64
Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr (2006) 1.63
Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One (2011) 1.63
Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study. BMC Infect Dis (2011) 1.62
New Delhi metallo-β-lactamase (NDM-1)-producing Klebsiella pneumoniae: case report and laboratory detection strategies. J Clin Microbiol (2011) 1.61
Men who have sex with men sensitivity training reduces homoprejudice and increases knowledge among Kenyan healthcare providers in coastal Kenya. J Int AIDS Soc (2013) 1.60
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (2004) 1.60
Molecular epidemiology of Mycobacterium tuberculosis in a South African community with high HIV prevalence. J Infect Dis (2009) 1.59
Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis (2013) 1.57
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics (2003) 1.57
Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr (2006) 1.56
Promoting retention in care: an effective model in an antiretroviral treatment service in South Africa. Clin Infect Dis (2007) 1.55
Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol (2005) 1.54
Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis (2012) 1.50
Tuberculosis transmission to young children in a South African community: modeling household and community infection risks. Clin Infect Dis (2010) 1.49
Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr (2009) 1.49
Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect Dis (2012) 1.46
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
Clinical decisions. Preexposure prophylaxis for HIV prevention. N Engl J Med (2012) 1.46
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS (2007) 1.46